跳至主要内容
临床试验/EUCTR2010-023969-21-GB
EUCTR2010-023969-21-GB进行中(未招募)1 期

Vascular Augmentation of Late-life Unremitted Depression - VALUeD, version 1.0

Gateshead Health NHS Foundation Trust0 个研究点目标入组 8 人开始时间: 2011年9月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
8

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

入选标准

  • •Age 50 years or older Clinically significant (unremitted) vascular depression, as defined above. MMSE >23 Medically stable BP < 150/90 (Quality and Outcomes Framework Audit standard) Patient has provided written informed consent for participation in the study prior to any study specific procedures
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range: 0
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range 0
  • •F.1.3 Elderly (>=65 years) yes
  • •F.1.3.1 Number of subjects for this age range 0

排除标准

  • •On calcium channel blocker Clinical evidence of dementia History or evidence of stroke History of bipolar or psychotic disorder Significant suicide risk Known hypersensitivity to amlodipine Severe renal or hepatic impairment Pregnancy, or women planning to become pregnant within next 12 months, or women who are breast feeding. Use of other investigational study drugs within 30 days prior to study entry (defined as date of randomisation into study) Previous participation in this study OPTIONAL MRI Sub Study only - Contraindications for MRI scanning (eg pacemaker in situ, metal fragments in eyes, or unwillingness to undergo MRI scanning)

研究者

相似试验